Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 2,006 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Discrete Clear all

Conditions: Stress Disorders, Post-Traumatic
Interventions: Cue-Centered Treatment (CCT), Trauma-Focused CBT (TF-CBT), Treatment as Usual, NIRScout; Behavioral · Device
Lead sponsor: Stanford University; Other
Eligibility: 7 Years to 18 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Sacramento, California • San Francisco, California

Conditions: Pediatric Crohns Disease, Pediatric Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions: Group educational activities, IBD educational website, Monthly check-in calls from program coordinator, Mentor, Fun group activities, Parent support group; Behavioral
Lead sponsor: Kelly Boone; Other
Eligibility: 10 Years to 17 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Spinal Cord Injuries
Interventions: Test Meals; Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Musculoskeletal Pain, Osteoarthritis, Tendinopathy, Sprains Strain
Interventions: Bone Marrow Aspirate Concentrate Injection; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorder, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Non-malignant Diseases Requiring Allogeneic HSCT
Interventions: IL-2; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: p16INK4a mRNA level assessment, organ-specific protein signatures assessment; Diagnostic Test
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 22 Years to 66 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions: XL102, Fulvestrant, Abiraterone, Prednisone; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 56
States / cities: Phoenix, Arizona • Tucson, Arizona • Carmichael, California + 52 more

Conditions: Freeze Dried Plasma in Healthy Volunteers
Interventions: Autologous Freeze Dried Plasma (FDP), Fresh Frozen Plasma (FFP); Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chronic Kidney Diseases, Metabolic Acidosis, Fatigue, Physical Endurance, Insulin Resistance, Mitochondrial Energetics, Diabetes
Interventions: Sodium bicarbonate, placebo; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 21 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Sacramento, California • Nashville, Tennessee

Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
Interventions: Anti-thymocyte globulin (rabbit), Blinatumomab, Cyclophosphamide, Fludarabine, G-CSF, Melphalan, Mesna, Rituximab, Tacrolimus, Thiotepa, HPC,A Infusion, CliniMACS, Sirolimus; Drug · Biological · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Healthy
Interventions: Atorvastatin, MGL-3196; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Respiratory Distress Syndrome
Interventions: Aerosolized lucinactant; Drug
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: 15 Minutes to 30 Minutes
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: San Diego, California

Conditions: Stress Urinary Incontinence, Pelvic Floor Disorders
Interventions: RP sling placement, SIS placement; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Manhasset, New York + 3 more

Conditions: Blepharospasm, Focal Dystonia
Interventions: repetitive transcranial magnetic stimulation (rTMS); Procedure
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy, Renal Insufficiency
Interventions: KBP-5074; Drug
Lead sponsor: KBP Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Evergreen Park, Illinois

Conditions: Post-polio Syndrome
Interventions: Flebogamma® 5% DIF, Placebo; Biological · Drug
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 4
States / cities: St Louis, Missouri • Syracuse, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Nonheme Iron Absorption
Interventions: My Pyramid menu days 1, 2, 3, 4, 5, 6 or 7; Behavioral
Lead sponsor: USDA Grand Forks Human Nutrition Research Center; Federal
Eligibility: 21 Years to 50 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Grand Forks, North Dakota

Conditions: Dementia, Cognitive Impairment, Cognitive Decline, Alzheimer Disease
Interventions: MyCog; Diagnostic Test
Lead sponsor: Northwestern University; Other
Eligibility: 45 Years and older
Enrollment: 57,589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Participants
Interventions: Etrumadenant; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Obesity, Overweight, Overeating, Weight, Childhood Obesity
Interventions: Family Based Behavioral Treatment; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 8 Years to 12 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Acute Promyelocytic Leukemia
Interventions: SY-2101, Arsenic Trioxide; Drug
Lead sponsor: Syros Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Birmingham, Alabama • Chicago, Illinois • Baltimore, Maryland + 5 more

Conditions: Olfactory Dysfunction, Smell Loss, Anosmia, Hyposmia
Interventions: Sudoku Puzzles, ScentCare (Olfactory Training Device); Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neonatal Prematurity, Hypotension
Interventions: Monitoring and biospecimen collection; Other
Lead sponsor: University of Iowa; Other
Eligibility: Up to 1 Week
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 1
States / cities: Iowa City, Iowa

Search by objective public record fields.

Child Characteristics, Neuromarkers, and Intervention Components Impacting Treatment Outcome: CCT, TF-CBT, TAU

Peer Mentoring to Improve Self-management in Youth With IBD

Feeding Regulation in SCI

Clinical Outcomes of Autologous Bone Marrow Aspirate Concentrate Injections for Musculoskeletal Conditions

Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD

A Novel Approach Utilizing Organ Specific Age Proteomics

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Ascending Doses of Autologous FDP vs FFP

Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Drug Interaction Study of MGL-3196 With Atorvastatin

Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants

Retropubic vs. Single-Incision Mid-Urethral Sling for Stress Urinary Incontinence

Brain Stimulation to Treat Blepharospasm or Meige Syndrome

Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment

Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome

Iron Bioavailability From MyPyramid Menus

Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial

A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants

Family Based Treatment for Weight Loss With Breakfast Prescription

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

Scents of Progress: Leveraging a Novel Device for Olfactory Training in Older Adults

Effects of Transitional Circulation in ELBW Infants